Company news
Vivos Therapeutics, Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Vivos Therapeutics Expands Strategic Alliance in Colorado and Seeks New Sleep Center Affiliations and Acquisitions Nationwide
February 24, 2025
Vivos Therapeutics to Participate in Fireside Chat with Water Tower Research on February 18, 2025 at 12: 00 pm ET.
February 18, 2025
Vivos Therapeutics Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 22, 2024
Vivos Therapeutics Reports Third Quarter 2024 Financial Results and Provides Operational Update
November 13, 2024
Vivos Therapeutics Schedules Release of Third Quarter 2024 Financial Results and Conference Call
November 12, 2024
Vivos Therapeutics Granted CPT® Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices From American Medical Association
October 7, 2024
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
September 18, 2024
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
September 17, 2024
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call
August 13, 2024
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
June 26, 2024
Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance
June 11, 2024
Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call
May 13, 2024
Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update
May 13, 2024
Vivos Therapeutics receives approval for Medicare reimbursement for flagship Oral Medical Devices
April 8, 2024
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call
March 27, 2024
Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update
March 27, 2024
Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds
February 14, 2024
Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA
January 7, 2024
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
November 28, 2023
Vivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apnea
November 28, 2023
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
November 13, 2023
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
November 8, 2023
Vivos Therapeutics agrees to nationwide distribution deal with in-home respiratory dealer Lincare
November 2, 2023
Vivos Therapeutics Closes $4 Million Private Placement
November 1, 2023
Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
October 30, 2023
Vivos Therapeutics Announces Reverse Stock Split
October 25, 2023
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
October 23, 2023
Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine
October 10, 2023
Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion
October 4, 2023
Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers
October 3, 2023
Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call
August 15, 2023
Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
August 13, 2023
Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call
August 9, 2023
Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update
June 7, 2023
Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call
June 5, 2023
Vivos Therapeutics Announces Additional Strategic Initiatives Aimed at Accelerating Anticipated Timeline for Cash Flow Positive Operations
May 8, 2023
Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update
March 29, 2023
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC
February 28, 2023
Vivos Therapeutics Regains Compliance with Nasdaq Listing Requirements
January 19, 2023
Vivos Therapeutics Closes $8 Million Private Placement
January 8, 2023
Vivos Therapeutics Announces Pricing of $8 Million Private Placement
January 4, 2023
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea
January 3, 2023
Vivos Therapeutics Reports Second and Third Quarter 2022 Financial Results and Provides Operational Update
December 19, 2022
Vivos Therapeutics Schedules Release of Second and Third Quarter 2022 Financial Results and Conference Call
December 15, 2022
Vivos Therapeutics Announces New Revenue Stream Through Strategic Medical Billing Relationship with Nexus Dental Systems
December 14, 2022
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Third Quarter 2022 Quarterly Report on Form 10-Q
November 27, 2022
Vivos Therapeutics Provides Update on Revenue Recognition Review
November 21, 2022
Vivos Therapeutics Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q
August 25, 2022
Vivos Therapeutics Provides Update on Second Quarter Earnings Delay
August 21, 2022
Vivos Therapeutics to Reschedule Second Quarter 2022 Financial Results Conference Call
August 14, 2022
Calls
The 5 newest of 21 calls. Every call is listed under its year.
- Vivos Therapeutics (NASDAQ:VVOS) Q2 2026 Earnings Call
Aug 14, 2026
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q1 2026 Earnings Call
May 20, 2026
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q4 2025 Earnings Call
Apr 15, 2026
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q3 2025 Earnings Call
Nov 19, 2025
Transcript - Vivos Therapeutics (NASDAQ:VVOS) Q2 2025 Earnings Call
Aug 19, 2025
Transcript